




Improved drug development with Capture Compound Mass Spectrometry

Capture Compound Mass Spectrometry (CCMS) is an innovative technology for the selective isolation of proteins or enzyme families in biological samples of various origins. CCMS reduces the complexity of the proteome and also permits a gel-free LC-MS/MS based analysis of small molecule – protein interactions. CCMS allows the discovery, isolation and profiling of any member of functional protein families within the diversity of a biological sample. During the drug development process CCMS can be used to gain insights in issues like drug – target interactions or the identification of off-target molecules (ImproMed). This information can be used to investigate the risk of unwanted

side effects like the identification and understanding of liver toxicity. In addition, CCMS can be used to identify relevant biomarkers early on in the Lead Optimization process. Another opportunity might be the detection of potential new indications for drugs in development. By using caprotec's CCMS technology, a major gain in the understanding of protein-drug interaction at any stage of the drug development process can be achieved, contributing to earlier GO/NO GO decisions, selection of most promising drug candidate before entering clinical development, and a major reduction in development cost.



Applications of CCMS in the drug development process

About caprotec bioanalytics

caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called Capture Compounds™. They enable a targeted isolation of proteins directly from complex biological samples. The technology is protected by a broad patent portfolio. caprotec bioanalytics was founded in 2006 by Prof. Dr. Hubert Köster, an acknowledged innovator and entrepreneur in the field of biotech. His track records include the foundation of Biosyntech, the first biotech company in Germany in 1981, the co-foundation of Milligen/Biosearch and the foundation of Sequenom Inc. As CEO and President of Sequenom he was responsible for one of the most successful US biotech IPOs at the NASDAQ. After closing a financing round of EUR 6 million, caprotec bioanalytics started operations in January 2008 in Berlin-Adlershof. The Company is supported by an international scientific advisory board including one Nobel Laureate.

In May 2010 caprotec bioanalytics completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS technology to analyze the binding characteristics and interaction of one undisclosed drug candidate with its human target proteins. "This project demonstrated that the CCMS technology is robust and yields high quality results that are complementary to our internal research efforts. We are very pleased with the outcome of this collaboration", stated Dr. Stephan Röver, Scientific Expert for Discovery Chemistry at Roche.

caprotec's **Capture Compound** technology is available from caprotec bioanalytics as:

- Customized **caproKits™** and Contract Service
- Ready-to-use **caproKits** in the field of signal transduction, epigenetic, and proteases.

References

- Köster, H. et al., *Assay Drug Dev Technol.* 2007, 5, 381-390
Fischer, J.J. et al., *Toxicol Sci.* 2010, 113(1), 243-53
Dalhoff, C. et al., *Chembiochem.* 2010, 11(2), 256-65
Kroll, F. et al., *IPT 2009*, 29
Fischer, J.J. et al., *Proteomics* 2011, 11, 1-9
Fischer, J.J. et al., *J. Proteomics* 2011, 75(10), 160-168

Contact

Headquarters caprotec bioanalytics GmbH

Volmerstrasse 5
D-12489 Berlin

Phone: +49 30 63 92 39 90

Fax: +49 30 63 92 39 89

Web: www.caprotec.com

Email: sales@caprotec.com

Copyright

© 2008-2012 caprotec bioanalytics GmbH. All rights reserved. Reproduction in whole or in part only with permission of caprotec bioanalytics GmbH.

Trademarks

caproBox, caprotec, caproKit, Capture Compound, caproBeads, caproMag, and ImproMed are Trademarks of caprotec bioanalytics GmbH. All other Trademarks belong to their respective owners.

Imprint

Entry in Commercial Register:

Registered Seat: Berlin, Germany

Register court: AG Berlin (Charlottenburg)

HRB 100 170 B

VAT Identification Number: 37/123/21157

Managing Director: Prof. Dr. Hubert Köster

Products & Services

CCMS technology is made available as ready to use caproKit reagents and services.

For more information please visit www.caprotec.com

Or contact us. Email: info@caprotec.com

Phone: +49 30 6392 3990

Products and Services are for Research use only.

© 2008-2012 caprotec bioanalytics GmbH